Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of nicotinamide adenine dinucleotide or precursor substance thereof in preparation of medicament for treating corneal epithelial defect

A technology of nicotinamide adenine and nicotinamide purine, which can be used in drug combinations, pharmaceutical formulations, and medical preparations containing active ingredients, etc., can solve problems such as limiting the clinical application of new therapies, achieve broad development and application prospects, and promote repair. , the effect of speeding up the repair

Active Publication Date: 2019-04-23
SHANDONG EYE INST
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are limitations in both traditional and new treatments, such as material sources and price factors, which greatly limit the clinical application of new treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of nicotinamide adenine dinucleotide or precursor substance thereof in preparation of medicament for treating corneal epithelial defect
  • Application of nicotinamide adenine dinucleotide or precursor substance thereof in preparation of medicament for treating corneal epithelial defect
  • Application of nicotinamide adenine dinucleotide or precursor substance thereof in preparation of medicament for treating corneal epithelial defect

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Mouse Corneal Nerve Injury Causes Reduced Protein Levels of Nicotinamide Phosphoribosyltransferase (NAMPT) in Corneal Epithelium

[0029] The experimental animals were C57bl / 6 male mice aged 6-8 weeks, which were purchased from Pengyue Experimental Animal Company in Jinan, Shandong Province. The experimental mice had no corneal defects, neovascularization or conjunctival damage.

[0030] Mice were generally anesthetized by intraperitoneal injection of pentobarbital sodium (50 mg / kg), and lidocaine eye drops were used for local anesthesia. The bulbar conjunctiva was cut at the outer canthus of the mouse to expose the optic nerve, and the nerve bundle outside the optic nerve sheath was separated. , The tweezers were clamped for 20-40 seconds to damage the corneal nerve bundles other than the optic nerve, and the bulbar conjunctiva and eyelids were sutured after surgery. The eyelid sutures were removed on the second day after operation, and the operated eyes were...

Embodiment 2

[0032] Example 2 Corneal Nerve Injury in Mice Causes Reduced Nicotinamide Adenine Dinucleotide Levels in the Cornea

[0033] The mouse corneal nerve injury model was established according to the method in Example 1.

[0034] The corneas of nerve-injured and control mice were taken, and nicotinamide adenine dinucleotide in the cornea was extracted by mechanical grinding and ultrasonic crushing, and nicotinamide adenine dinucleotide was detected using NAD / NADH quantitative detection kit (purchased from sigma company, catalog number MAK037) Dinucleotide content. The result is as image 3 As shown, corneal nerve injury in mice resulted in decreased levels of nicotinamide adenine dinucleotide in the cornea.

Embodiment 3

[0035] Example 3 Nicotinamide adenine dinucleotide or its precursor substance nicotinamide mononucleotide improves and treats corneal epithelial defect in mice caused by corneal nerve injury

[0036] The mouse corneal nerve injury model was established according to the method in Example 1.

[0037] Nicotinamide adenine dinucleotide (40μM-2mM) or its precursor nicotinamide mononucleotide (100μM-5mM) was administered once every 24 hours by subconjunctival injection (5μL / eye), continuously medicine 3 times, the mice with corneal nerve injury were treated, and the results were as follows: Figure 4 The results showed that supplementation of nicotinamide adenine dinucleotide or nicotinamide mononucleotide can better improve the corneal epithelial defect caused by corneal nerve injury.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of nicotinamide adenine dinucleotide or a precursor substance thereof in preparation of a medicament for treating corneal epithelial defect, and relates to the technical field of ophthalmic medicaments. Research shows that the expression of the nicotinamide phosphotransferase in epithelial cells after the corneal injury is abnormal, so that the level of the nicotinamide purine dinucleotide in the corneal epithelial cells is reduced, and the nicotinamide phosphodinucleotide can promote the repair of the corneal epithelial cells, therefore, applying the nicotinamide adenine dinucleotide or the precursor substance thereof to local area of an eye can effectively accelerate the repair of corneal epithelial cells and effectively treat corneal epithelial defects. According to the invention, the nicotinamide adenine dinucleotide or the precursor substance thereof is applied to the preparation of the medicament for treating corneal epithelial defect, and the medicament has wide development and application prospects.

Description

technical field [0001] The invention relates to the technical field of ophthalmic medicines, in particular to the application of nicotinamide adenine dinucleotide or its precursor in the preparation of medicines for treating corneal epithelial defects. Background technique [0002] Nicotinamide adenine dinucleotide (NAD, also known as coenzyme I) is a metabolic regulator, and NAD is involved in physiological and pathological processes such as energy metabolism, oxidative damage, and aging. The intracellular NAD synthesis pathway is divided into de novo synthesis pathway and salvage synthesis pathway. The de novo synthesis pathway of NAD starts from tryptophan and passes through formylkynurenine, kynurenine, 3-hydroxykynurenine, 3-hydroxy-2-aminobenzoic acid, quinolinic acid and nicotinic acid mono Nucleotides are eventually synthesized into NAD. The NAD salvage synthetic pathway is mainly synthesized from nicotinamide, nicotinic acid and nicotinamide riboside as precursors...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7084A61K31/455A61K31/405A61K31/706A61P27/02
CPCA61K31/405A61K31/455A61K31/706A61K31/7084A61P27/02
Inventor 李雅周庆军史伟云李晶马修彬杨玲玲
Owner SHANDONG EYE INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com